Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Prices for High-Cost Techs Will Settle Down as They Penetrate Market with Public Health Coverage: MHLW Bureau Chief
July 10, 2018
- Tokyo Govt to Launch Support Program for Drug Discovery Startups to Solve Obstacles to Fundraising, IP Strategy
July 10, 2018
- Reduce Dose, or Discontinue Biologics for Patients with Low RA Disease Activity: Report
July 9, 2018
- Govt Dodges Lawmaker Inquiry on Timing of 2019 Drug Price Revision
July 9, 2018
- LDP Lawmakers to Sort Out Life Science Issues over This Summer
July 6, 2018
- Council OKs Public Knowledge-Based Submissions for New Azathioprine, Temozolomide Indications
July 5, 2018
- Govt Likely to Allow 600 Billion Yen Rise for FY2019 Social Security Budget Request
July 4, 2018
- Several Brand-Name Drug Makers Intend to Withdraw “G1” LLPs
July 4, 2018
- LDP Lawmakers Launch New Study Group on Life Science Industry
July 3, 2018
- MHLW OKs 1st Pfizer Biosimilar, Add’l Indications and Dosages
July 3, 2018
- MHLW Approves Entyvio, Imfinzi, Lynparza Breast Cancer Use, and More
July 3, 2018
- PMDA Reveals First 2 Cases of MID-NET Regulatory Use
July 2, 2018
- LDP’s Patch Panel Boots Up with Bigwig Noda as Chairman
June 28, 2018
- MHLW to Remove Pregnancy Contraindication for 3 Immunosuppressants
June 27, 2018
- Ryukaikon Working Group to Discuss Rebates Offered to Make Up for Higher Invoice Prices
June 26, 2018
- New LDP Study Group to Kick Off with Focus on Innovation in Life Science
June 25, 2018
- PMDA Wants to Increase Safety Staffers to 270 by FY2023: Official
June 21, 2018
- Public Insurance Should Cover Pricy Drugs, Rather than Cold Medicines: MHLW’s Top MD Bureaucrat
June 21, 2018
- PMDA Slips to Second in Time-to-Approval Ranking
June 21, 2018
- LDP’s Pharma Study Group to Form Panel for Patch Medications, Proposal Due Out This Autumn
June 20, 2018
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…